AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

Once metronidazole enters the organism by passive diffusion and activated in the cytoplasm of susceptible anaerobic bacteria, it is reduced; this process includes intracellular electron transport ...

The four selected RCTs compared antiseptics to metronidazole or clindamycin. In two studies control treatment consisted of a single oral dose of 2 g metronidazole, in one study of a 7-day regime ...

or Metronidazole 250 mg orally three times daily for 7 days, or Clindamycin 300 mg orally twice daily for 7 days Bacterial vaginosis (BV) is a condition characterized by a loss of the indigenous ...

Addresses the significant threat of antimicrobial resistance.

Metronidazole exerts antibacterial effects in an anaerobic environment against most obligate anaerobes. Once metronidazole enters the organism by passive diffusion and activated in the cytoplasm ...

AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.